Cargando…
Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis
BACKGROUND AND AIMS: Metalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. I...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072739/ https://www.ncbi.nlm.nih.gov/pubmed/35529854 http://dx.doi.org/10.3389/fimmu.2022.885229 |
_version_ | 1784701126509068288 |
---|---|
author | Bauer, Alicja Habior, Andrzej |
author_facet | Bauer, Alicja Habior, Andrzej |
author_sort | Bauer, Alicja |
collection | PubMed |
description | BACKGROUND AND AIMS: Metalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC. METHODS: The MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit. RESULTS: Higher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 ± 62.6 vs 21.3 ± 7.4 ng/mL, p < 0.001 for healthy subjects; 68.9 ± 62.6 vs 22.7 ± 7.6 ng/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 ± 62.6 vs 37.2 ± 17.4 ng/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 ± 85.8 vs 61.6 ± 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p < 0.01). CONCLUSIONS: Our study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC. |
format | Online Article Text |
id | pubmed-9072739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90727392022-05-07 Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis Bauer, Alicja Habior, Andrzej Front Immunol Immunology BACKGROUND AND AIMS: Metalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC. METHODS: The MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit. RESULTS: Higher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 ± 62.6 vs 21.3 ± 7.4 ng/mL, p < 0.001 for healthy subjects; 68.9 ± 62.6 vs 22.7 ± 7.6 ng/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 ± 62.6 vs 37.2 ± 17.4 ng/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 ± 85.8 vs 61.6 ± 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p < 0.01). CONCLUSIONS: Our study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC. Frontiers Media S.A. 2022-04-22 /pmc/articles/PMC9072739/ /pubmed/35529854 http://dx.doi.org/10.3389/fimmu.2022.885229 Text en Copyright © 2022 Bauer and Habior https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Bauer, Alicja Habior, Andrzej Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title | Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title_full | Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title_fullStr | Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title_full_unstemmed | Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title_short | Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis |
title_sort | concentration of serum matrix metalloproteinase-3 in patients with primary biliary cholangitis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072739/ https://www.ncbi.nlm.nih.gov/pubmed/35529854 http://dx.doi.org/10.3389/fimmu.2022.885229 |
work_keys_str_mv | AT baueralicja concentrationofserummatrixmetalloproteinase3inpatientswithprimarybiliarycholangitis AT habiorandrzej concentrationofserummatrixmetalloproteinase3inpatientswithprimarybiliarycholangitis |